Drew Barrymore on Menopause: What She's Said, What It Means, and What You Can Learn From It

What Drew Barrymore Has Actually Said About Perimenopause

Barrymore has been specific, not vague. She first addressed perimenopausal symptoms on The Drew Barrymore Show in 2023, describing hot flashes in real time in front of her studio audience. In a candid moment that circulated widely on social media, she called out the heat she was feeling and connected it explicitly to perimenopause rather than brushing it off. Later, in interviews with People magazine and on her own show, she described the experience as something she had not fully anticipated, noting that nobody had really walked her through what the transition would feel like in her body.

In 2024, Barrymore continued the conversation, discussing mood shifts and what she described as a sense of "going through something" without a clear road map. She has not publicly confirmed a specific treatment protocol, and no credible source as of this writing attributes a named prescription medication or supplement regimen to her. Any claim circulating online that she takes a specific drug should be treated as unverified unless she states it herself.

The value of her disclosure is not the medical detail. It is the normalization. Many women arrive at perimenopause having received almost no anticipatory guidance from their clinicians, and research published in Menopause found that fewer than 20 percent of OB-GYN residency programs in the United States included dedicated menopause curriculum as of 2020. Barrymore naming her symptoms on national television does work that the medical system has often failed to do.

Why the Timing of Her Disclosure Matters Clinically

Barrymore was in her late 40s when she began speaking publicly. That places her squarely in the statistical window for perimenopause. The average age of the final menstrual period in the United States is 51.4 years, meaning the perimenopausal transition typically begins in the mid-to-late 40s and can last four to eight years. Women who follow Barrymore and are in the same age range may be experiencing the same symptoms right now without a name for them.

What "Perimenopause" Actually Means

Perimenopause is not a single moment. It is a biological transition marked by fluctuating and eventually declining estradiol and progesterone, irregular cycles, and rising FSH. The STRAW+10 staging system, published in Climacteric and endorsed by major menopause societies, defines perimenopause as beginning with variable cycle length of more than 7 days and ending 12 months after the final menstrual period. Hot flashes, the symptom Barrymore described most vividly, are caused by thermoregulatory instability driven by estrogen withdrawal acting on the hypothalamus.

The Symptoms She Named: A Clinical Breakdown

Hot flashes and night sweats are the symptoms Barrymore has described most publicly. These are classified as vasomotor symptoms (VMS), and they affect approximately 75 percent of women during the menopause transition. For roughly 25 to 30 percent of those women, VMS are severe enough to interfere with work, sleep, and quality of life.

Hot Flashes: What Is Actually Happening

A hot flash is a sudden sensation of heat, typically beginning in the chest or face, lasting one to five minutes, and sometimes followed by chilling and sweating. The trigger is a narrowed thermoneutral zone in the hypothalamus, a change driven by declining estrogen. Women with higher BMI, African American women, and women who smoke have higher VMS prevalence and severity, based on data from the Study of Women's Health Across the Nation (SWAN).

Mood Changes and Brain Fog

Barrymore has also referenced emotional turbulence and cognitive shifts. These are real, measurable phenomena. Estrogen receptors are distributed throughout the brain, including in the prefrontal cortex and hippocampus, regions involved in memory and executive function. A longitudinal analysis from the Penn Ovarian Aging Study found that women in perimenopause showed significantly lower verbal memory scores than they had in their premenopausal baseline. These changes are transient for most women but can be distressing and are frequently misattributed to stress or depression.

What Does Drew Barrymore Take? What We Know and Don't Know

This is the most-searched question about Barrymore and menopause. The honest answer: she has not publicly disclosed a specific treatment regimen as of January 2025.

She has spoken about working with doctors and about seeking help, which is clinically meaningful in itself, because many women delay or never seek treatment for menopause symptoms. The Menopause Society (formerly NAMS) 2023 Position Statement on hormone therapy states that MHT is the most effective treatment for VMS and is appropriate for healthy women under 60 or within 10 years of menopause onset, absent contraindications. Whether Barrymore uses MHT, a non-hormonal option, or lifestyle modifications is her private information.

Below is a framework clinicians at WomanRx use when a patient presents with the same symptom picture Barrymore described: visible hot flashes, mood disruption, and a sense of being unprepared for the transition.

The WomanRx Perimenopausal Symptom Triage Framework

| Symptom severity | First consideration | Second-line if needed | |---|---|---| | Mild VMS (fewer than 7/day, not disrupting sleep) | Lifestyle: cool environment, layered clothing, limiting alcohol and spicy food | Low-dose SSRI/SNRI (e.g., paroxetine 7.5 mg, venlafaxine 75 mg) | | Moderate-to-severe VMS | Menopausal hormone therapy (estradiol + progestogen if uterus intact) | Fezolinetant 45 mg (FDA-approved 2023, non-hormonal NK3 receptor antagonist) | | Mood and sleep disruption dominant | Rule out primary depression/anxiety; consider MHT if VMS is driver | CBT for menopause (Menopause MindBody program has RCT support) | | Genitourinary symptoms (GSM) | Vaginal estrogen (low-dose, systemically negligible absorption) | Ospemifene or intravaginal DHEA (prasterone) |

The Evidence Base for Perimenopause Treatment

Menopausal Hormone Therapy (MHT)

MHT remains the most studied and most effective treatment for VMS. The 2022 NAMS Hormone Therapy Position Statement (updated and reaffirmed in 2023) gives MHT its strongest recommendation for women with bothersome VMS who are under 60 and within 10 years of menopause onset. The Women's Health Initiative (WHI), which was published in JAMA in 2002 and frightened a generation of women and clinicians away from hormone therapy, enrolled women with a mean age of 63. Applying its findings to women in their late 40s and early 50s, as Barrymore is now, represents a misuse of the data that menopause specialists have spent two decades correcting.

Estradiol is available as a patch, gel, spray, or oral pill. For women with an intact uterus, a progestogen must be added to protect the endometrium. Micronized progesterone (Prometrium) has a more favorable safety profile than synthetic progestins, particularly regarding breast cancer risk, based on data from the French E3N cohort study.

Non-Hormonal FDA-Approved Options

Fezolinetant (Veozah), approved by the FDA in May 2023, is a neurokinin-3 (NK3) receptor antagonist that acts centrally to reduce the frequency and severity of hot flashes. In the SKYLIGHT 1 and SKYLIGHT 2 trials, fezolinetant 45 mg reduced hot flash frequency by approximately 60 percent versus placebo at week 12. It carries no hormonal activity and is an option for women who cannot or choose not to use MHT.

Paroxetine mesylate 7.5 mg (Brisdelle) is the only SSRI approved specifically for VMS. Off-label use of venlafaxine 75 mg also has meaningful trial data behind it. These are useful for women with contraindications to hormones.

What the Evidence Gap Looks Like for Women

Many VMS trials have enrolled predominantly white, postmenopausal women. African American and Hispanic women, who have higher rates of VMS based on SWAN data, are underrepresented. Perimenopausal women specifically, the life stage Barrymore is in, have fewer dedicated trial data than postmenopausal women. This is a real gap, and clinicians extrapolate from postmenopausal data for perimenopausal patients more than the field would like to admit. Any claim of a precision evidence base for perimenopausal treatment should be read with that caveat in mind.

Perimenopause and Fertility: The Contraception Conversation Nobody Has

This is one of the most clinically important points that celebrity coverage almost never addresses. Perimenopause does not mean infertility. Ovulation continues intermittently during the transition, and unintended pregnancy rates in women over 40 are not trivial. The CDC reports that approximately 75 percent of pregnancies in women aged 40 to 44 are unintended.

ACOG recommends continuing contraception until 12 consecutive months have passed since the final menstrual period, which is the clinical definition of menopause. For a woman in her late 40s with irregular cycles who is starting to experience hot flashes, the question of birth control is not academic.

Contraception Options During Perimenopause

• Hormonal IUDs (levonorgestrel, e.g., Mirena): Provide contraception and can reduce irregular bleeding. The progestogen component may also serve as the progestogen arm of MHT if low-dose systemic estrogen is added.
• Copper IUD: Non-hormonal, effective. Does not affect VMS or cycle pattern.
• Low-dose combined oral contraceptives (COCs): Appropriate for non-smoking, healthy perimenopausal women under 50 without cardiovascular risk factors. They suppress VMS and regulate cycles but mask the hormonal picture, making it harder to know when menopause has occurred.
• Progestogen-only pill (POP): Suitable across most health profiles.
• Barrier methods: Effective when used consistently but have higher typical-use failure rates.

Estrogen-containing contraceptives at standard doses are distinct from MHT and deliver significantly higher estrogen exposure. They should not be conflated.

Who This Applies To: Life Stage Guide

Not every woman reading this is in the same situation as Barrymore. Here is how the conversation maps to different life stages.

Reproductive Years (Under 40)

If you are under 40 and experiencing irregular cycles, hot flashes, or elevated FSH, premature ovarian insufficiency (POI) should be evaluated. POI affects approximately 1 in 100 women under 40 and is a distinct condition from natural perimenopause. It carries different risks, particularly for bone density and cardiovascular health, and treatment with MHT in POI is not the same clinical calculation as MHT at 50.

Trying to Conceive

If you are trying to conceive and experiencing cycle changes that suggest declining ovarian reserve, an AMH level and antral follicle count (AFC) can give useful information. Work with a reproductive endocrinologist, not a primary care provider, for fertility planning in this scenario.

Perimenopause (Approximately 45 to 55)

This is Barrymore's current life stage. You may have irregular periods, night sweats, hot flashes, sleep disruption, mood shifts, or joint pain. FSH and estradiol levels fluctuate wildly and a single test is rarely diagnostic. The Menopause Society advises against relying on hormone levels alone to diagnose perimenopause; clinical history and symptom pattern are the primary diagnostic tools.

Post-Menopause (12+ Months After Final Period)

VMS can persist for years or decades after menopause. The SWAN study found that the median duration of VMS was 7.4 years, with African American women experiencing symptoms for a median of 10.1 years. If your symptoms are bothersome at any point post-menopause, treatment is available and the risk-benefit calculation remains favorable for most healthy women under 60.

Why Celebrity Disclosure Matters Clinically (and Where Its Limits Are)

Dr. Elena Vasquez, MD, WomanRx Medical Reviewer and OB-GYN, puts it directly: "When a woman with Barrymore's visibility says 'I'm having a hot flash right now on television,' she does something that a pamphlet in a waiting room cannot. She makes the symptom visible, speakable, and normal. The risk is that women then wait to see what the celebrity does next instead of booking an appointment with their own clinician."

That tension is real. Celebrity health disclosure accelerates awareness but can also create a parasocial substitute for medical care. The most useful thing Barrymore's openness can do is send women to their providers earlier, not later.

The Women's Health Initiative fallout is an instructive parallel. After 2002, MHT prescriptions in the United States dropped by more than 50 percent within two years, driven largely by media coverage that overgeneralized the findings. Research published in JAMA Internal Medicine estimated that this decline in MHT use may have contributed to thousands of preventable deaths from cardiovascular disease and osteoporotic fractures in women for whom the therapy would have been appropriate. Media framing of women's health issues carries real clinical consequences, in both directions.

What to Ask Your Clinician If You Identify With Barrymore's Experience

If Barrymore's statements resonated because you are experiencing similar symptoms, the following questions are worth taking to your next appointment.

1. Can we review my cycle history and symptom pattern to see if I'm in perimenopause?
2. Is there any value in checking my FSH, estradiol, or AMH at this point, or will it change our plan?
3. What is my personal risk-benefit profile for MHT, given my history?
4. If I'm not a candidate for hormones, what non-hormonal options have the strongest evidence for my specific symptoms?
5. Do I still need contraception, and if so, which method fits my overall health picture?
6. Should I have a baseline bone density scan (DXA) now?

A clinician who cannot or will not discuss these questions may not be current on menopause medicine. The Menopause Society maintains a Menopause Practitioner Locator for finding a certified specialist.

Bone Health: The Symptom Nobody Talks About

Barrymore has not, to public knowledge, discussed bone density. But it belongs in any complete perimenopause conversation. Estrogen is the primary regulator of bone resorption in women. Bone loss accelerates sharply in the two to three years before and after the final menstrual period, with women losing an average of 10 percent of trabecular bone mass in the first five years of menopause. The U.S. Preventive Services Task Force recommends DXA screening for osteoporosis beginning at age 65 in average-risk women, but women with early menopause or risk factors warrant earlier screening.

MHT preserves bone density and reduces fracture risk, a benefit that is sometimes underweighted when discussing its risk-benefit profile in the context of VMS treatment.